Validated : Actualité Validated en direct - P2 | Bourse Reflex
Accueil > Tags > Validated

  • Toutes les actualités en rapport avec « Validated »

10/05 15:55 Validated - Apricus Biosciences Announces First Quarter 2011 Financial Results Conference Call

28/04 16:10 Validated - Apricus Biosciences Requests Approval of Vitaros(R) as a Treatment for Erectile Dysfunction in Europe

28/04 11:05 Validated - Apricus Biosciences Requests Approval of Vitaros(R) as a Treatment for Erectile Dysfunction in Europe

28/04 09:30 Validated - Apricus Biosciences to Present at the FSX Investor Conference in San Francisco on April 28, 2011

13/04 19:45 Validated - Apricus Biosciences Files for Orphan Drug Designation for RayVa(TM)

05/04 18:55 Validated - Apricus Biosciences' CEO Interviewed by WallStreetCorner.com

31/03 16:45 Validated - Apricus Biosciences Expands Patent Coverage in Mexico for Its Erectile Dysfunction Drug, Vitaros(R)

24/03 15:55 Validated - Apricus Biosciences Adopts Shareholder Rights Plan

22/03 14:55 Validated - Apricus Biosciences Announces Poster Presentations on Progress of PrevOnco(TM) in Combination With NexACT(R) Technology at the American Association for Cancer Research 2011 Annual Meeting

16/03 14:05 Validated - New Crucial DDR3-1333MHz BOM-controlled RDIMM Server Memory Now Available

15/03 15:30 Validated - Apricus Biosciences Announces Formation of Clinical Advisory Board as Part of Its Plans to Further the Clinical Development of Femprox(R)

10/03 16:00 Validated - Apricus Biosciences to Present at the Bio-Europe Spring 2011 Conference

08/03 16:00 Validated - Apricus Biosciences Announces Removal of Auditor's "Going Concern" Opinion From Its 2010 Form 10-K and Increased Cash Reserves

01/03 15:15 Validated - Apricus Biosciences Announces Expanded European Patent Coverage for MycoVa(TM) for Nail Fungus

17/02 15:15 Validated - Apricus Biosciences and FDA Initiate PrevOnco(TM) SPA Phase III Clinical Protocol Discussion

14/02 16:15 Validated - Apricus Biosciences and Neopharm Group Sign Licensing Agreement for Vitaros(R) in Israel for up to USD 4.35 Million, Plus Royalties

10/02 16:15 Validated - Apricus Biosciences to Present Review of Commercialization Plans for Vitaros(R) and Development of Product Pipeline at BioPartnering North America Conference(TM)

24/01 12:30 Validated - Raptor Pharmaceutical Completes Enrollment in Pivotal Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis

19/01 17:45 Validated - Apricus Biosciences Reports Additional Analysis Showing That MycoVa(TM) is as Effective for the Treatment of Nail Fungus as the Current European Standard of Care for Topical Therapy, Loceryl(R)

28/10 14:44 Validated - VUPEN Vulnerability Management Solutions Approved for Purchase by Government and Federal Agencies